InformAI is pleased to announce that we are the recipient of a $1.55M award from the Cancer Prevention and Research Institute of Texas (CPRIT) to support product development and commercialization of the AI-enabled head & neck radiation oncology guided dose prediction platform, RadOnc-AI.
CPRIT was created by the Texas Legislature in 2007 as an investment fund to lead the Lone Star State’s fight against cancer. Over the past 10 years, CPRIT has awarded over $3 billion in awards to Texas medical institutions and companies. Inform AI was one of five awardees in the CPRIT product development category.
Our RadOnc-AI product uses artificial intelligence (AI) to predict the optimal radiation dose for a patient’s radiation plan (called a directive). Estimating the radiation dose is tedious, iterative and time-consuming. An oncology team can spend 10+ hours creating a single patient directive. The radiation dose plan must be sufficient enough to kill the tumor, but minimal enough so that the radiation does not damage nearby healthy tissues and organs.
The RadOnc-AI product solves current pain points in the radiation oncology clinical workflow and fills a critical gap in cancer care, particularly for patients not able to get treatment at larger academic hospitals. Cancer patients treated at larger hospitals with specialized doctors tend to have better outcomes than those treated at smaller non-specialty hospitals, where there is a reduced survival rate.
InformAI teamed with the University of Texas Southwestern Medical Center (UTSW) in Dallas, Texas for this effort. The RadOnc-AI prototype has been tested in a UTSW research setting with 350 patients.
InformAI is a technology company focused on advancing healthcare through analytics. We use the power of artificial intelligence in practical healthcare applications to improve patient outcomes and streamline clinician workflows. To empower clinicians with the best possible solutions, we leverage our strategic partnerships within the Texas Medical Center, the world’s largest medical provider with 10 million annual patient encounters. Our products provide data-driven analytics to assist physicians with decisions at the point of care to provide personalized patient solutions. Our products focus on high impact medical conditions including head and neck cancer, cardiac/thoracic surgery, and sinus conditions. For more information, visit informai.com
CPRIT was created by the Texas Legislature and approved by a statewide vote in 2007 to lead the Lone Star State’s fight against cancer. In 2019, Texas voters again voted overwhelmingly to continue CPRIT with an additional $3 billion for a total $6 billion investment in cancer research and prevention. To date, CPRIT has awarded over $3 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has also recruited more than 281 distinguished researchers to Texas, supported the establishment, expansion or relocation of 51 companies to Texas and generated over $7.66 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided over 8.1 million life-saving cancer prevention and early detection services to Texans in all 254 counties. Learn more at https://cprit.texas.gov.